Human papillomavirus vaccines: WHO position paper

Biologicals

Volumn 37, Issue 5, 2009, Pages 338-344

  WHO, ^a  

^a NONE

Author keywords

Cervical cancer; Dysplasia; Human papillomavirus; Vaccine; WHO position

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE;

ANTIBODY RESPONSE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG STORAGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; PAPANICOLAOU TEST; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SINGLE DRUG DOSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT; VIRUS TRANSMISSION; WOMEN'S HEALTH; WORLD HEALTH ORGANIZATION;

ALPHAPAPILLOMAVIRUS; HEALTH PLANNING GUIDELINES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; WORLD HEALTH ORGANIZATION;

HUMAN PAPILLOMAVIRUS;

EID: 69749089002     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.04.005     Document Type: Conference Paper

References (34)

1. Human papillomavirus (HPV) vaccine. Background paper (September 2008), WHO, Geneva. http://www.who.int/immunization/documents/positionpapers/en/index.html [accessed 24.03.09]
2. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals (2007), WHO, Geneva. http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.05_eng.pdf [accessed 25.09.08]
3. Smith J.S., Melendy A., Rana R.K., and Pimenta J.M. Age-specific prevalence of infection with human papillomavirus in females: a global review. Journal of Adolescent Health 43 Suppl. 4 (2008) S5.e1-S5.e62
4. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369 (2007) 1861-1868
5. Stanley M., Lowy D.R., and Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24 Suppl. 3 (2006) S106-S113
6. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
7. Merck USA. Highlights of prescribing information: GARDASIL [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, Recombinant], 2008. Whitehouse Station, NJ; 2007. http://www.merck.com/product/usa/pi_circulars/g/gardasil_pi.pdf [accessed 25.09.08].
8. ® product information: human papillomavirus vaccine type 16 and 18 (Recombinant AS04 adjuvanted), 2007. Boronia, Victoria, Australia; 2007. http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/94/ FileName/7A14FBAEA16635A2DD7A68ED78E8FDDC/P1_Cervarix.pdf [accessed 15.05.08].
9. Villa L.L. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. International Journal of Infectious Diseases 11 Suppl. 2 (2007) S17-S25
10. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Adolescent Health 40 (2007) 564-571
11. Pagliusi S.R., and Aguado M.T. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
12. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases 196 (2007) 1438-1446
13. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
14. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 95 (2006) 1459-1466
15. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Human Vaccines 3 (2007) 109-115
16. Harper D.M. Sustained immunogenicity and high efficacy against HPV 16/18 related cervical neoplasia: long-term follow-up through 6.4 years in women vaccinated with Cervarix (GSK's HPV 16/18 AS04 candidate vaccine). Presented at the Annual Meeting on Women's Cancer of the Society for Gynecologic Oncology, Tampa, Florida, USA, 9-12 March, 2008. Abstract in Gynecologic Oncology 109 (2008) 158
17. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 356 (2007) 1928-1943
18. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 356 (2007) 1915-1927
19. Palefsky J, Giuliano A, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. Abstract of presentation at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference; 13 November 2008. http://www.eurogin.com [accessed 24.03.09].
20. Giuliano A, Palefsky J, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. In: Abstract of presentation at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference; 13 November 2008. http://www.eurogin.com [accessed 24.03.09].
21. Harper D.M. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecologic Oncology 110 Suppl. 1 (2008) S11-S17
22. See No. 28/29, 2007. p. 252-9.
23. See No. 5, 2009. p. 37-40.
24. Kim J.J., Brisson M., Edmunds W.J., and Goldie S.J. Modelling cervical cancer prevention in developed countries. Vaccine 26 Suppl 10 (2008) K76-K86
25. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer 97 (2007) 1322-1328
26. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., and Reynales-Shigematsu L. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 (2007) 128-139
27. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine 3 (2006) e138
28. Techakehakij W., and Feldman R.D. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 26 (2008) 6258-6265
29. Goldie S.J., O'Shea M., Diaz M., and Kim S.Y. Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Reproductive Health Matters 16 (2008) 86-96
30. Conclusion: moderate quality of scientific evidence to support HPV vaccination of young adolescent girls to prevent cervical cancer later in life. http://www.who.int/immunization/HPV_Grad_Adol_girls.pdf [accessed April 2009]
31. Conclusion: moderate quality of scientific evidence to support administration of quadrivalent HPV vaccine to young adolescent girls to prevent anogenital warts later in life. http://www.who.int/immunization/HPV_Grad_Warts.pdf [accessed April 2009]
32. Conclusion: very low quality of scientific evidence to support vaccination of young males to reduce risk of female cervical cancer. http://www.who.int/immunization/HPV_Grad_Males.pdf [accessed April 2009]
33. Conclusion: very low quality of scientific evidence to support vaccination of HIV-infected young adolescent girls to prevent cervical cancer later in life. http://www.who.int/immunization/HPV_Grad_HIV.pdf [accessed April 2009]
34. Conclusion: low quality of scientific evidence that a booster dose of HPV vaccine is not required to ensure long-term protection against cervical cancer. http://www.who.int/immunization/HPV_Grad_Booster.pdf [accessed April 2009]